HK1250926A1 - 抑制劑及其應用 - Google Patents

抑制劑及其應用

Info

Publication number
HK1250926A1
HK1250926A1 HK18110386.1A HK18110386A HK1250926A1 HK 1250926 A1 HK1250926 A1 HK 1250926A1 HK 18110386 A HK18110386 A HK 18110386A HK 1250926 A1 HK1250926 A1 HK 1250926A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
Prior art date
Application number
HK18110386.1A
Other languages
English (en)
Inventor
Anne Bertolotti
Indrajit Das
Agnieszka Krzyzosiak
Adrien Rousseau
Kim Schneider
Anna Gudny Sigurdardottir
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1505971.0A external-priority patent/GB201505971D0/en
Priority claimed from GBGB1505975.1A external-priority patent/GB201505975D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of HK1250926A1 publication Critical patent/HK1250926A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
HK18110386.1A 2015-04-08 2018-08-14 抑制劑及其應用 HK1250926A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1505971.0A GB201505971D0 (en) 2015-04-08 2015-04-08 Inhibitors and their uses
GBGB1505975.1A GB201505975D0 (en) 2015-04-08 2015-04-08 Inhibitors and their uses
PCT/GB2016/050991 WO2016162689A1 (en) 2015-04-08 2016-04-08 Inhibitors and their uses

Publications (1)

Publication Number Publication Date
HK1250926A1 true HK1250926A1 (zh) 2019-01-18

Family

ID=55759894

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110386.1A HK1250926A1 (zh) 2015-04-08 2018-08-14 抑制劑及其應用
HK18110390.5A HK1250929A1 (zh) 2015-04-08 2018-08-14 用於選擇磷酸酶選擇性抑制劑和非選擇性磷酸酶抑制劑的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110390.5A HK1250929A1 (zh) 2015-04-08 2018-08-14 用於選擇磷酸酶選擇性抑制劑和非選擇性磷酸酶抑制劑的方法

Country Status (15)

Country Link
US (5) US11154519B2 (zh)
EP (2) EP3280404B1 (zh)
JP (2) JP6868568B2 (zh)
KR (2) KR102572217B1 (zh)
CN (2) CN107820518B (zh)
AU (2) AU2016246098B2 (zh)
BR (2) BR112017021522B1 (zh)
CA (2) CA2982033C (zh)
DK (2) DK3280404T3 (zh)
ES (2) ES2886571T3 (zh)
HK (2) HK1250926A1 (zh)
IL (2) IL254928B (zh)
MX (2) MX2017012924A (zh)
SG (2) SG11201708246TA (zh)
WO (2) WO2016162689A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017012924A (es) 2015-04-08 2018-08-01 Medical Res Council Metodos para seleccionar inhibidores selectivos de fosfatasa e inhibidores no selectivos de fosfatasa.
GB201709927D0 (en) * 2017-06-21 2017-08-02 Medical Res Council Biochemically defined functional and selective activity and methods for selecting selective inhibitors of holophosphatases targeting their regulatory subunits
WO2024009280A1 (en) * 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3592935A (en) * 1969-12-11 1971-07-13 Sandoz Ag Substituted benzylidene hydrazines as anti-inflammatory agents
US3982020A (en) 1970-03-17 1976-09-21 Sandoz, Inc. Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation
GB1550401A (en) * 1976-01-07 1979-08-15 Hexachimie Hydrazine derivatives their preparation and their use
AU7802700A (en) * 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
JP2007506435A (ja) * 2003-09-25 2007-03-22 アカディア ファーマシューティカルズ，インコーポレーテッド 神経ペプチドｆｆ受容体２アゴニストによる神経因性疼痛の処置
FR2893844B1 (fr) 2005-11-28 2008-02-01 Centre Nat Rech Scient Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
DE602006006578D1 (de) 2006-10-04 2009-06-10 Agronomique Inst Nat Rech Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen
EP1908464A1 (en) 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
WO2014138298A1 (en) 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
US20150246140A1 (en) 2014-02-10 2015-09-03 California Institute Of Technology Compositions and methods for modulating sleep and wakefulness
KR20170027737A (ko) 2014-07-02 2017-03-10 인플렉티스 바이오사이언스 O-알킬-벤질리덴구아니딘 유도체 및 미스폴딩된 단백질의 축적 관련 장애의 치료를 위한 치료 용도
CN107074752B (zh) 2014-07-02 2021-10-26 英费列特斯生命科学公司 苯亚甲基胍衍生物在治疗蛋白质构象紊乱方面的治疗用途
MX2017012924A (es) * 2015-04-08 2018-08-01 Medical Res Council Metodos para seleccionar inhibidores selectivos de fosfatasa e inhibidores no selectivos de fosfatasa.
US20180230105A1 (en) * 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds

Also Published As

Publication number Publication date
CA2982040C (en) 2023-10-31
AU2016246099B2 (en) 2020-09-10
US11337941B2 (en) 2022-05-24
BR112017021507A2 (pt) 2018-07-03
US20200197337A1 (en) 2020-06-25
AU2016246099A1 (en) 2017-10-26
SG11201708246TA (en) 2017-11-29
CN107820518B (zh) 2023-04-21
JP2018517402A (ja) 2018-07-05
BR112017021522B1 (pt) 2024-02-06
US20180111896A1 (en) 2018-04-26
CA2982033C (en) 2024-01-02
IL254916A0 (en) 2017-12-31
BR112017021507B1 (pt) 2023-10-31
MX2017012926A (es) 2017-12-20
KR20180018491A (ko) 2018-02-21
JP6868568B2 (ja) 2021-05-12
US20220313628A1 (en) 2022-10-06
DK3280404T3 (da) 2021-11-08
MX2017012924A (es) 2018-08-01
EP3280404A1 (en) 2018-02-14
AU2016246098A1 (en) 2017-10-26
EP3280404B1 (en) 2021-10-06
EP3280405B1 (en) 2021-07-07
HK1250929A1 (zh) 2019-01-18
IL254928B (en) 2022-01-01
US11154519B2 (en) 2021-10-26
ES2886571T3 (es) 2021-12-20
CA2982040A1 (en) 2016-10-13
WO2016162689A1 (en) 2016-10-13
KR102602998B1 (ko) 2023-11-15
AU2016246098B2 (en) 2020-09-17
WO2016162688A1 (en) 2016-10-13
BR112017021522A2 (pt) 2018-07-03
IL254916B (en) 2021-10-31
DK3280405T3 (da) 2021-09-06
CN107820518A (zh) 2018-03-20
SG11201708249SA (en) 2017-11-29
IL254928A0 (en) 2017-12-31
CA2982033A1 (en) 2016-10-13
CN107709291B (zh) 2021-03-12
CN107709291A (zh) 2018-02-16
JP2018517668A (ja) 2018-07-05
ES2897712T3 (es) 2022-03-02
US20180125801A1 (en) 2018-05-10
US11364211B2 (en) 2022-06-21
KR20180009740A (ko) 2018-01-29
EP3280405A1 (en) 2018-02-14
US11331286B2 (en) 2022-05-17
KR102572217B1 (ko) 2023-08-28
US20200297668A1 (en) 2020-09-24
JP6882189B2 (ja) 2021-06-02

Similar Documents

Publication Publication Date Title
IL258636A (en) Acc inhibitors and uses thereof
HK1256997A1 (zh) Tyk2抑制劑及其用途
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
IL277239B (en) mdm2 inhibitors and combinations thereof
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
GB201605126D0 (en) Inhibitors and their uses
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL280863A (en) Ototaxin inhibitors and their uses
IL265139B (en) Dopamine-b-hydroxylase inhibitors
HK1249108A1 (zh) Mir-92抑制劑及其用途
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201612860D0 (en) Inhibitors
IL263949A (en) Complement inhibitors and their uses
GB201501004D0 (en) Inhibitors
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
HK1250926A1 (zh) 抑制劑及其應用
GB201520949D0 (en) Inhibitors
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB2543375B (en) Compounds and their uses
GB2545167B (en) Cloches and use thereof
GB201404332D0 (en) Selective glycosidase inhibitors and uses thereof
GB201404330D0 (en) Selective glycosidase inhibitors and uses thereof